Newsletter | January 25, 2023

01.25.23 -- Cell & Gene Sponsors: How Can You Help Your CDMO Help You?
 
New Podcast Episode
From The Editor
How You Can Help Your CDMO Help You?
Outsourced Pharma Live

A panel of industry experts provides advice on making the CDMO relationship work better, and how to optimize your outsourcing outcomes. In October 2022, Outsourced Pharma Live's “What’s Driving The Cell & Gene Therapy Outsourcing Capacity Cycle?” panelists discussed the identified macro and micro trends impacting dealmaking at CDMOs. Exclusive data from BioPlan Associates was also presented. Learn what to be on the lookout for as well as how to prepare and take advantage of (another) life cycle in our industry — this time in the cell and gene therapy space.
Featured Editorial
These Top 2022 Global Bioprocessing Trends Will Affect The Industry In 2023
By Shriya Bhatkhande, BioPlan Associates

For yet another year, COVID-19 and pandemic-related factors shaped the biopharmaceutical industry. It stretched supply chains and claimed qualified staff who otherwise would have been developing other drugs. BioPlan Associates, which publishes an annual industry survey, looks back on the biggest trends of 2022.
Industry Insights
MAM Solutions For Process And Product Control Of Biotherapeutic Proteins
Article | By Nick Pittman, Magnus Wetterhall, and Scott Berger, Ph.D., Waters Corporation

With industry-leading scientific expertise and customer support, we have pioneered solutions to some of the most pressing challenges facing customers interested in adopting MAM into their organizations.
Addressing The Challenge Of Scalability In Viral Vectors
White Paper | By Henry George and Lisa Freeman-Cook, MilliporeSigma

Learn more about a wide range of solutions to facilitate the delivery of gene therapy by addressing the challenges related to viral vector manufacture and scale-up.
Standardizing Viral Vector Manufacturing, Producer Cell Line Development
Poster | By Cristina Nogueira, Ben M. Alberts, Jordan Wright, Helen Maunder, Kyriacos A. Mitrophanous, Nicholas G. Clarkson, and Daniel C. Farley, Oxford Biomedica

The TRiP System allows suppression of transgene expression during upstream processes, resulting in enhanced vector yield and purity, simplifying downstream processes.
How The inSeption Group Cooperativity Program Quickly Built A Client’s Medical Writing Team
Article | inSeption Group

The Cooperativity Program’s goal is to help ISG clients build and strengthen their in-house departments — medical writing or otherwise — to reach their utmost potential.
Adherent Versus Suspension Processes For Viral Vector Manufacturing
Article | AGC Biologics

In adherent cell culture, cells are grown while attached to a substrate as monolayers. In suspension cell culture, cells are free-floating in the culture medium. Which offers more benefits?
mRNA Manufacturing Workflow
Infographic | Cytiva

Therapies based on messenger RNA, such as mRNA vaccines, have revolutionary potential. Learn more about key objectives, considerations, and strategies in mRNA manufacturing.
Outsourced Pharma Live
 

Available On Demand! Throughout the year, chief editor Louis Garguilo brings together industry experts to discuss some of the biggest challenges being faced by both sponsors and CDMOs. Our archived videos can be accessed at any time by registered site users.